The efficacy of Topical Clascoterone versus systematic spironolactone for treatment of acne vulgaris: A systematic review and network meta-analysis.

Autor: Basendwh MA; Dermatology Department, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia., Alharbi AA; Dermatology Department, King Saud University Medical City, Riyadh, Saudi Arabia., Bukhamsin SA; Family Medicine Department, Al-Ahsaa Health Cluster, Al-Ahsaa, Saudi Arabia., Abdulwahab RA; College of Medicine, Umm Alqura University, Makkah, Saudi Arabia., Alaboud SA; College of Medicine, Umm Alqura University, Makkah, Saudi Arabia.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2024 May 30; Vol. 19 (5), pp. e0298155. Date of Electronic Publication: 2024 May 30 (Print Publication: 2024).
DOI: 10.1371/journal.pone.0298155
Abstrakt: Objectives: This study aimed to evaluate the effectiveness of topical clascoterone (TC) compared to oral spironolactone for acne vulgaris treatment.
Methods: A computerized search through PubMed/MEDLINE, SCOPUS, and the Cochrane Library was conducted to find relevant papers. We used the "netmeta" and "meta" packages for network meta-analysis (NMA) in RStudio 1.2.5019 (2009-2019 RStudio, Inc.) to conduct all of our statistical tests.
Results: Seven articles (n = 2,006 patients) were included. The fixed-effect size showed that TC 1% bis in die (BID) showed potential effectiveness in reducing the inflammatory and non-inflammatory lesion count compared to placebo (Standardized mean difference, SMD = -0.27, 95% CI: -0.36 to -0.17) and (SMD = -0.31, 95% CI: -0.41 to -0.22), respectively. The random-effect size showed that TC 1% BID was significantly associated with a 12-week treatment success compared to placebo (Odds ratio, OR = 2.44, 95% CI: 1.12 to 5.30). Spironolactone 200 mg was associated with a significant reduction in total lesion count (SMD = -4.46, 95% CI: -5.60 to -3.32).
Conclusion: TC appears to reduce both inflammatory and non-inflammatory lesion count and may lead to treatment success. Spironolactone at 200 mg showed potential effectiveness in terms of total lesion count reduction. These results suggest that both TC and Spironolactone could be beneficial in treating patients with acne vulgaris.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Basendwh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje